The Lancet

This article from The Hindu explains brain aneurysms and subarachnoid hemorrhages (SAH) in the context of Kim Kardashian's recent aneurysm diagnosis. It describes SAH as the least known but most devastating type of stroke, with historical mortality rates as high as 45%. The piece highlights celebrity cases, including Emilia Clarke and Sharon Stone, who survived SAH. It details symptoms such as thunderclap headaches and vision problems, and notes that aneurysms often go undetected until rupture. The article cites a Lancet study showing a 3.2% prevalence of unruptured aneurysms, with average diagnosis age of 50 and higher incidence in women. It emphasizes that early diagnosis and treatment are critical for successful outcomes, though specific evolving treatments are not detailed in the provided text.

1 reports · 1 sources · Updated Jul 21, 07:19 AM UTC

GLP-1 weight-loss drugs, now used by 11% of U.S. adults, are reducing alcohol cravings and changing drinking habits, according to clinical trials and industry observations. Research published in The Lancet and JAMA Psychiatry shows semaglutide lowers drinks per drinking day and alcohol cravings. Bars and restaurants report customers increasingly ordering one premium cocktail then switching to non-alcoholic drinks, threatening the traditional 'second round' revenue stream. The trend creates risks for spirits brands reliant on volume consumption but opportunities for premium single-serve and alcohol-free products. Industry operators note the behavioral shift is most pronounced at the second drink order.

1 reports · 1 sources · Updated Jul 20, 07:21 PM UTC

A new analysis published in The Lancet Diabetes & Endocrinology challenges the widespread belief that yo-yo dieting, or weight cycling, is more harmful than remaining overweight. Professors Faidon Magkos and Norbert Stefan reviewed decades of research involving humans and animals, concluding there is no strong causal evidence that weight cycling causes long-term metabolic damage or disproportionate muscle loss. While weight regain reverses the health benefits of weight loss, such as improved blood sugar and pressure levels, it returns individuals to their baseline risk rather than worsening their condition. The authors argue that higher adiposity, not weight fluctuation, is the primary driver of metabolic risks like diabetes and cardiovascular disease. This finding is particularly relevant with the rise of effective weight-loss drugs that may lead to weight regain if discontinued. The study encourages patients and clinicians to pursue weight loss efforts without fear of metabolic ruin, emphasizing that intermittent weight reduction offers meaningful health improvements and that giving up on weight management poses greater risks than attempting it.

1 reports · 1 sources

A global medical consensus has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant change, published in The Lancet, results from a decade-long process involving over 22,000 participants, including patients and professionals from six continents. The previous name was deemed misleading as it focused on ovarian cysts, which are actually immature follicles and not present in all cases. The new terminology, PMOS, better reflects the condition's nature as a complex hormonal and metabolic disorder affecting approximately 10-13% of women. The term highlights three key aspects: polyendocrine disturbances, metabolic risks such as type 2 diabetes and cardiovascular disease, and ovarian issues like infertility. Experts argue that this renaming will improve patient care by shifting clinical focus away from solely gynecological symptoms to a broader understanding of the lifelong health risks involved, including mental health and metabolic complications. The decision aims to reduce stigma and ensure comprehensive treatment strategies for those affected.

1 reports · 1 sources

In this column from The Verge's Optimizer newsletter, senior reviewer Victoria Song explores the complexities of personalized health through the lens of her own experience with polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS). Song highlights how the global medical establishment's decision to rename the condition reflects its nature as a hormonal and metabolic disorder rather than purely a reproductive one. She illustrates the limitations of current personalized health solutions by comparing her symptoms and treatment response—such as insulin resistance and effectiveness of Metformin—with those of her esthetician, who suffers from different manifestations like cystic acne and responds better to dietary changes. The article argues that while personalized health is considered the holy grail of medicine, algorithms currently struggle to account for the vast variability in how chronic conditions manifest in different individuals. Song uses this personal narrative to critique the overpromising nature of health tech companies and wellness influencers who claim their gadgets can universally optimize health, emphasizing that effective treatment often requires nuanced, individualized approaches that technology has yet to fully master.

1 reports · 1 sources

A recent hantavirus outbreak linked to a cruise ship departing from Argentina highlights the growing intersection of climate change and public health. While the World Health Organization assures that the risk of a pandemic is low, the incident underscores warnings that rising global temperatures expand the habitats of disease-carrying rodents. In Argentina, hantavirus cases have nearly doubled in the past year, resulting in 32 deaths, driven by extreme weather patterns including historic droughts followed by intense rainfall that boosted rodent populations. Major news outlets like CNN and the Associated Press are credited for connecting this specific outbreak to broader climate trends, contrasting with media tendencies to ignore climate links in disaster reporting. With 2026 predicted to be the hottest year on record due to El Niño and climate change, experts warn that hotter planets are deadlier planets. The article emphasizes that while more research is needed to definitively link this specific outbreak to climate change, the trend of infectious diseases spreading to new areas via vectors like mosquitoes and ticks is a confirmed global health threat exacerbated by warming temperatures.

1 reports · 1 sources

This week marked significant progress in global health, environmental protection, and medical technology. A landmark study published in The Lancet revealed that the RTS,S malaria vaccine has significantly reduced child mortality in Ghana, Kenya, and Malawi, avoiding one in eight child deaths since its rollout. Currently, twenty-five African countries offer the vaccination, with the World Health Organization highlighting its potential to change mortality trajectories despite financing challenges. In environmental news, a Dutch court ruled that bottom trawling in the Dogger Bank marine protected area is unlawful, establishing a legal precedent that governments must regulate such activities in protected zones. This decision pressures other European nations to follow suit, with Greece already announcing a ban. Additionally, advancements in artificial intelligence offered new hope for early pancreatic cancer detection. An AI model developed by the Mayo Clinic successfully identified disease signatures up to three years before clinical diagnosis, potentially improving survival rates for this deadly cancer. Finally, Virginia became the latest US state to mandate paid medical leave for workers, enhancing labor rights. These developments collectively highlight positive strides in public health, ecological conservation, and technological innovation.

1 reports · 1 sources

A systematic review and meta-analysis published in The Lancet examines the association between antidepressant use during pregnancy and the risk of autism and ADHD in children. Medical experts from UK institutions, including the Royal College of Obstetricians and Gynaecologists and the University of Liverpool, welcome the findings as reassuring. The study, covering over 600,000 pregnancies involving antidepressant use, suggests that observed links are likely due to confounding by indication and genetic factors rather than medication effects. Experts emphasize that untreated maternal mental health issues pose significant risks, including suicide, which remains a leading cause of maternal death in the UK. The research highlights the importance of distinguishing between medication effects and underlying maternal conditions through robust study designs, such as sibling comparisons. Clinicians urge women to seek personalized care and avoid stopping necessary treatments based on misinformation, stressing that informed, shared decision-making is crucial for maternal and child well-being.

1 reports · 1 sources

Nancy J. Cox, a distinguished virologist and leading authority on influenza surveillance, pandemic preparedness, and infectious disease response, has passed away at the age of 77. Born on July 21, 1948, in Emmetsburg, Iowa, USA, Dr. Cox dedicated her career to advancing public health security and understanding viral threats. Her extensive work significantly influenced global strategies for managing infectious disease outbreaks and preparing for potential pandemics. She died from glioblastoma on April 24, 2026, in Atlanta, Georgia. This obituary, published by The Lancet, highlights her profound contributions to the field of virology and her lasting impact on international health policies. As an expert in her field, Cox played a pivotal role in shaping responses to influenza viruses, ensuring better preparedness for future health crises. Her death marks the loss of a key figure in medical science who bridged research and practical application in disease control. The announcement serves as a tribute to her legacy, emphasizing her dedication to saving lives through rigorous scientific inquiry and proactive health measures. Her life's work remains a cornerstone in the ongoing fight against infectious diseases worldwide.

1 reports · 1 sources

Autologous stem-cell transplantation (ASCT) has long been the standard of care for younger patients diagnosed with mantle cell lymphoma, a status established following the publication of the first European Mantle Cell Lymphoma Network trial in 2005. However, this longstanding medical paradigm is now facing significant scrutiny. A recent commentary highlights that the central role of ASCT is being firmly challenged by new findings published in The Lancet. These results stem from the TRIANGLE study, conducted by Martin Dreyling and his colleagues. The study presents evidence that questions the necessity or supremacy of ASCT in current treatment protocols for this specific type of lymphoma. This development marks a potential shift in clinical guidelines and therapeutic strategies for younger patients, suggesting that alternative treatments may offer comparable or superior outcomes. The medical community is now re-evaluating the historical reliance on transplantation as the primary intervention, signaling a possible end to its reign as the undisputed cornerstone of care for mantle cell lymphoma patients.

1 reports · 1 sources

A recent analysis of the TRIANGLE phase 3 clinical trial, published in The Lancet, provides critical insights into the optimal first-line treatment for patients aged 18–65 with mantle cell lymphoma. Following a 55-month follow-up period, the study evaluated three treatment arms to determine the efficacy of adding autologous stem-cell transplantation (ASCT) to ibrutinib-containing regimens. The results demonstrated that both groups receiving ibrutinib achieved significant improvements in failure-free survival and overall survival compared to standard therapies. However, the addition of ASCT to the ibrutinib regimen offered no supplementary clinical benefit and was associated with increased toxicity. Consequently, researchers conclude that induction treatment combining ibrutinib with R-CHOP plus R-DHAP (or R-DHAOx), followed by two years of ibrutinib maintenance, should be established as the new standard of care for younger patients. This finding marks a pivotal shift in therapeutic protocols, prioritizing effective pharmacological intervention over high-toxicity transplant procedures for this specific demographic, potentially improving quality of life while maintaining superior survival outcomes.

1 reports · 1 sources

This seminar, published in The Lancet, addresses encephalitis as an urgent global health emergency that contributes significantly to morbidity and mortality worldwide. The article emphasizes the critical need for improved clinical strategies to manage brain inflammation effectively. It categorizes the etiologies of encephalitis into two primary groups: infectious causes, particularly pathogenic viruses, and autoimmune causes involving emerging ranges of autoantibodies. The authors highlight pragmatic clinical approaches designed to help healthcare professionals recognize and distinguish between these common causes in routine practice. A key focus is placed on the importance of pre-test impressions, which are refined through valuable and relatively simple investigations. Specifically, the text advocates for the use of serum and cerebrospinal fluid testing for nucleic acids and autoantibodies. These diagnostic tools are essential for identifying the precise causative agent, thereby enabling targeted treatment. By improving diagnostic accuracy and speed, the seminar suggests there are substantial opportunities to reduce the severe health impacts associated with encephalitis, offering a structured framework for clinicians to handle both viral and autoimmune presentations effectively.

1 reports · 1 sources

This correspondence features the authors' reply to comments by David J Sher regarding a phase 3 clinical trial comparing intensity-modulated photon radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) for treating oropharyngeal cancer. The authors highlight a key finding that proton therapy allows for de-intensified chemoradiation, significantly reducing high-grade toxicities and gastrostomy tube dependency. Specifically, the rate of gastrostomy tube dependency was 40.2% in the IMRT group compared to 26.8% in the IMPT group. Sher had expressed concern that the reported rates of severe xerostomia were higher in this trial than in the previous RTOG 1016 study, noting that 45% of IMPT patients and 33% of IMRT patients experienced severe dry mouth. The authors address these concerns by contextualizing their findings against the RTOG 1016 data, where 61.5% of patients required gastrostomy tubes. This exchange underscores the ongoing evaluation of toxicity profiles and quality-of-life outcomes in advanced radiation therapies for head and neck cancers, emphasizing the potential benefits of proton therapy in reducing treatment-related burdens.

1 reports · 1 sources

This perspective article from The Lancet examines the profound implications of integrating artificial intelligence (AI) and generative AI into medical practice. It highlights how these technologies challenge traditional understandings of clinical work performed by human practitioners, raising critical questions about both the limitations and benefits of AI in healthcare settings. The authors argue that amidst the rapid adoption of AI, it is essential to re-evaluate the fundamental therapeutic value inherent in human-to-human interaction within clinical medicine. The text emphasizes that while AI offers significant possibilities, it also presents pitfalls that necessitate a deeper discussion on pervasive misconceptions regarding the nature of the human mind. Specifically, it addresses the concept of the societally embedded human mind, suggesting that current practical applications may overlook the complex social and psychological dimensions of patient care. The article serves as a call to balance technological advancement with a renewed appreciation for the irreplaceable role of human empathy and interaction in healing processes, ensuring that the integration of AI enhances rather than diminishes the core values of medical practice.

1 reports · 1 sources

The Lancet has published the results of the Integral-1 study, a double-blind, randomized phase 3 clinical trial evaluating the efficacy and safety of two novel antibiotic combinations: cefepime–nacubactam and aztreonam–nacubactam. The study compared these new treatments against the standard care regimen of imipenem–cilastatin in patients suffering from complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis. The findings indicate that both cefepime–nacubactam and aztreonam–nacubactam are viable and effective treatment options for Gram-negative infections associated with these conditions. Crucially, the trial highlights their potential utility in treating infections caused by antimicrobial-resistant strains, addressing a significant challenge in modern healthcare. This research contributes valuable data to the field of infectious disease management, offering new therapeutic avenues for clinicians dealing with resistant bacterial pathogens. The publication in a prestigious medical journal underscores the scientific rigor and clinical relevance of these findings for global health practices.

1 reports · 1 sources

This correspondence highlights a significant discrepancy regarding life expectancy estimates for Monaco in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. While the GBD study is recognized as an invaluable resource for global health metrics, its estimate of 80.4 years for Monaco's life expectancy in 2023 is substantially lower than figures provided by official sources. Typically, Monaco is synonymous with world-leading longevity, with data from the Monaco Government and United Nations reports consistently ranking it among the highest globally. Specifically, the Monegasque Demography Observatory reports a life expectancy at birth of 87.0 years for the 2022–2024 period. This notable gap between the GBD's modeling and local official statistics raises concerns about the accuracy of health metrics for microstates within large-scale global studies. The article serves as a critical analysis of these conflicting data points, emphasizing the need for careful interpretation of global health estimates when applied to unique demographic contexts like Monaco.

1 reports · 1 sources

A new modelling study published in The Lancet addresses the critical need for robust metrics to guide vaccine selection within Gavi, the Vaccine Alliance's country budgets. As decisions regarding which vaccines to deploy become increasingly significant for national immunisation programmes, the ability to compare the relative health impacts of different vaccines is essential for informed decision-making. This research presents vaccine impact ratios derived from an analysis of 117 countries at the subregional level. These ratios serve as a vital tool to complement existing evidence, thereby supporting more effective planning and prioritisation strategies. By providing a standardized method for comparing vaccine efficacy and impact, the study aims to enhance the efficiency of resource allocation in global health initiatives. The findings are particularly relevant for policymakers and health officials involved in shaping national immunisation agendas, offering data-driven insights to optimize public health outcomes. Ultimately, this work underscores the importance of quantitative analysis in strengthening the strategic framework of international vaccine alliances and ensuring that limited healthcare budgets are utilized to maximize health benefits across diverse populations.

1 reports · 1 sources

This correspondence, published in The Lancet, addresses a recent multi-institutional study led by Steven J. Frank and colleagues regarding the comparison of photon and proton therapies for treating oropharyngeal squamous cell carcinoma. While the author congratulates the team on successfully completing the study, they emphasize that significant questions remain unresolved. A primary focus of the discussion is the difference in side effects between intensity-modulated radiation therapy (IMRT), which uses photons, and intensity-modulated proton therapy (IMPT). Specifically, the text highlights the risk of grade 3 xerostomia, a severe form of dry mouth. According to the Common Toxicity Criteria for Adverse Events (CTCAE), this condition is defined by an inability to eat orally, the need for tube feeding or total parenteral nutrition, or an unstimulated salivary flow rate of less than 0.1 mL/min. The correspondence serves as a critical academic commentary, urging further investigation into the clinical implications and toxicity profiles of these competing radiation treatment modalities for head and neck cancer patients.

1 reports · 1 sources

This commentary from The Lancet highlights the critical role of vaccines as one of the most impactful and cost-effective public health interventions available today. Drawing on decades of evidence from randomized controlled trials and epidemiological studies, the article underscores the significant positive impact of immunization programs on population health. However, it identifies a growing paradox: as vaccination efforts successfully reduce the incidence of debilitating childhood diseases, the perceived necessity of immunization may diminish among the general public. This phenomenon is exacerbated by rising vaccine hesitancy and the widespread dissemination of misinformation. Consequently, the authors argue that it is increasingly vital to continue demonstrating the tangible, real-world benefits of vaccines globally. The piece emphasizes the need to balance robust scientific evidence with policy requirements to maintain public trust and support for immunization initiatives, particularly in countries supported by Gavi, the Vaccine Alliance. By addressing these challenges, health policymakers can better communicate the ongoing importance of vaccines in preventing disease outbreaks and sustaining public health gains.

1 reports · 1 sources

This article, published in The Lancet as part of a series examining medicine in unusual settings, provides an in-depth analysis of healthcare delivery within United Kingdom prisons. Authored by Talha Burki, the report investigates the unique challenges and operational realities faced by medical professionals working in correctional facilities. It highlights the complexities of providing adequate medical care to incarcerated populations, who often present with higher rates of chronic diseases, mental health issues, and substance abuse disorders compared to the general public. The piece explores the structural barriers, resource limitations, and ethical dilemmas inherent in prison healthcare systems. By focusing on the UK context, the report offers critical insights into how penal institutions manage health services, the integration of prison healthcare with national health systems, and the impact of incarceration on patient outcomes. This analysis serves as a vital contribution to understanding the intersection of public health, human rights, and criminal justice, emphasizing the need for improved standards and accessibility in prison medical practices.

1 reports · 1 sources

This correspondence, published in The Lancet, serves as an official reply from the authors of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. It addresses concerns raised by Grant M A Wyper and colleagues regarding a notable discrepancy between the GBD 2023 life expectancy estimates for the microstate of Monaco and figures previously published by local authorities. The authors acknowledge the complexities inherent in estimating health metrics for small populations, which often present unique statistical challenges due to limited data volume and high variability. Rather than dismissing the critique, the response welcomes further academic engagement and dialogue on methodological improvements for small-population estimation. The primary purpose of this piece is to offer several technical clarifications to explain the differences in the reported data. By addressing these specific discrepancies, the authors aim to enhance the transparency and accuracy of global health statistics. This exchange highlights the ongoing scientific process of refining epidemiological models and ensuring that global studies accurately reflect local realities, particularly for unique demographic entities like Monaco.

1 reports · 1 sources

This correspondence published in The Lancet critically analyzes the results of a phase 3 clinical trial conducted by Steven J. Frank and colleagues regarding proton therapy for oropharyngeal cancer. The authors argue that the reported improvement in overall survival, despite equivalent progression-free survival compared to photon therapy, likely stems from confounding factors rather than genuine therapeutic efficacy. A central point of contention is the discrepancy between intention-to-treat and per-protocol analyses. The critics note that if proton therapy truly enhanced survival, the observed difference should have been attenuated when accounting for patients who crossed over from photon to proton therapy, assuming no extreme bias in the crossover population. However, this attenuation was not demonstrated in the trial data. Consequently, the correspondence suggests that the claimed survival benefits may be misleading. This analysis highlights the complexities involved in interpreting local therapy trials where survival metrics diverge, urging caution in accepting the superiority of proton therapy based on the current evidence. The piece serves as a scientific rebuttal aimed at clarifying statistical interpretations in oncology research.

1 reports · 1 sources

This correspondence, published in The Lancet, responds to a recent review by Marcello Ienca and colleagues regarding the increasing erosion of public trust in health institutions. The authors express strong agreement with the premise that restoring emotional engagement and resonance is essential for rebuilding this trust. However, they critique the original review for overlooking youth advocacy as a critical, scalable strategy. Citing the World Health Organization (WHO) framework, the correspondents argue that youth advocacy serves as an effective co-production mechanism that encompasses most aspects of the solutions proposed by Ienca et al. The letter highlights the FRESHAIR4Life initiative as a prime example of how engaging young people can bridge the gap between health systems and the public. By integrating youth voices into health policy and communication strategies, institutions can foster greater transparency and reliability. This piece emphasizes the need for health leaders to adopt inclusive approaches that leverage the energy and perspective of younger generations to counteract skepticism and strengthen the foundational relationship between healthcare providers and the communities they serve.

1 reports · 1 sources

This correspondence, published in The Lancet, addresses the critical issue of trust dynamics within the healthcare sector, specifically focusing on the impact of artificial intelligence. The authors respond to a previous review by Marcello Ienca and colleagues, which identified a paradox where rigorous medical institutions lose credibility while unaccountable voices gain it. The correspondents argue that the emergence of large language model (LLM)-based chatbots represents a qualitatively distinct escalation of this trust paradox. They contend that this phenomenon extends significantly beyond the social media dynamics previously described, introducing new complexities to patient-provider relationships and information verification. The text highlights the urgent need to understand how automated conversational agents influence public perception of medical authority and accuracy. By distinguishing LLM interactions from traditional social media misinformation, the authors emphasize the unique challenges posed by AI in health communication. This analysis serves as a scholarly commentary on the evolving landscape of digital health trust, urging further scrutiny of how algorithmic tools may exacerbate existing credibility gaps between established healthcare systems and informal information sources.

1 reports · 1 sources

This editorial from The Lancet reflects on the significant evolution of psychedelic research over the past two decades. Twenty years ago, the journal highlighted how blanket bans on psychedelic drugs in many countries hindered safe, controlled medical investigations into their potential benefits for mental health conditions. At that time, the scientific community faced substantial regulatory barriers that stifled progress. However, the landscape has shifted dramatically since then. The editorial notes that the authors of the 2006 piece could not have predicted the current political and scientific climate. Specifically, it highlights a recent executive order signed by the President of the United States, which aims to dramatically accelerate access to new medical research and treatments based on psychedelic substances. This development marks a pivotal moment in the renaissance of psychedelic medicine, transitioning from strict prohibition to active governmental support for clinical exploration. The article underscores the contrast between past restrictions and present-day efforts to unlock therapeutic potentials, signaling a new era for mental health treatment innovations involving psychedelics.

1 reports · 1 sources

Complicated urinary tract infections (cUTIs) and acute pyelonephritis continue to be significant drivers of hospital admissions globally, placing a substantial burden on healthcare systems through increased antibiotic consumption and rising costs. The medical community faces growing challenges in effectively treating these conditions due to the escalating prevalence of antibiotic resistance among Gram-negative bacterial pathogens. Specifically, the rise of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales and carbapenem-resistant bacteria has complicated therapeutic approaches. This commentary highlights the urgent need for innovative treatment strategies, focusing on emerging β-lactam and β-lactamase inhibitor combinations. These new pharmacological approaches aim to overcome resistance mechanisms and improve clinical outcomes for patients suffering from severe urinary tract infections. As traditional antibiotics become less effective, the development and deployment of these advanced inhibitors are critical for maintaining effective healthcare responses to resistant bacterial infections worldwide.

1 reports · 1 sources

Peru is actively working to improve healthcare accessibility for patients suffering from cleft conditions, particularly those residing in remote and underserved regions of the country. This significant expansion of surgical care and comprehensive treatment services is being driven by intensive capacity-building initiatives. A key component of this strategy involves the leadership and active participation of local volunteers, who are instrumental in delivering these essential medical services to hard-to-reach populations. The report highlights the collaborative effort to bridge the gap in healthcare infrastructure, ensuring that individuals with cleft lip and palate defects receive necessary surgical interventions and ongoing care. By focusing on local empowerment and volunteer-led programs, Peru aims to create a sustainable model for treating congenital facial anomalies. This approach not only addresses immediate surgical needs but also strengthens the overall healthcare system's ability to manage such conditions in rural areas. The initiative underscores a commitment to equitable health access, reducing the burden on families who previously lacked resources or proximity to specialized medical centers. This development marks a positive step forward in public health outreach within the nation.

1 reports · 1 sources

For decades, medical consensus regarded the thymus as a vestigial organ critical only for T-cell education during childhood, assuming it lost relevance after involuting into fatty tissue post-adolescence. This long-standing dogma was recently challenged by clinical studies linking thymus removal during thoracic surgery to poor patient outcomes, suggesting its continued importance. Now, artificial intelligence (AI) is driving further breakthroughs in understanding this organ. Recent research leveraging AI technologies provides new insights into the potential role of the thymus across the entire human lifespan, rather than just early development. This shift in perspective highlights the organ's significance in adult health and immunity, moving beyond the traditional view of it as merely a childhood structure. The integration of advanced computational methods allows for a deeper analysis of thymic function and its impact on long-term health outcomes, potentially reshaping surgical practices and immunological theories. This development underscores the growing intersection of technology and medicine in reevaluating fundamental biological assumptions.

1 reports · 1 sources

Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a comprehensive review by 56 international scientific, clinical, and patient organizations. The change, published in The Lancet, aims to more accurately reflect the condition's systemic nature, emphasizing its metabolic and hormonal impacts beyond ovarian changes. Experts argue that the previous term caused misinterpretation, as the 'cysts' are actually arrested follicles, and obscured associated risks like insulin resistance, type 2 diabetes, and cardiovascular disease. Despite the nomenclature update, diagnostic criteria and treatment protocols remain unchanged. Diagnosis still requires two of three factors: ovulatory dysfunction, excess androgens, or ovarian changes. Treatments continue to include hormonal contraceptives, metformin, and lifestyle modifications. The transition to the new name will be implemented over the next three years, involving updates to medical records and international classification systems like the WHO's ICD. This shift seeks to improve public and professional understanding of PMOS as a multisystemic disorder affecting women of reproductive age, addressing the fact that up to 70% of cases currently go undiagnosed.

1 reports · 1 sources

An international coalition of 56 medical organizations has proposed renaming Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition’s nature as a widespread hormonal and metabolic dysfunction rather than solely an ovarian issue, as many patients do not have ovarian cysts. The proposal, published in The Lancet and presented at the European Congress of Endocrinology, resulted from over a decade of debate and input from more than 14,000 patients. Experts argue that the previous name contributed to delayed diagnoses, stigma, and fragmented care by misclassifying the disorder. The new terminology is intended to redirect medical focus toward long-term chronic management, including screening for cardiovascular and metabolic problems. The consortium plans for the World Health Organization and the International Classification of Diseases to adopt PMOS as the international standard by 2028. This shift seeks to enhance research funding, improve clinical guidelines, and reduce the health and economic burden affecting approximately 170 million reproductive-age women worldwide, particularly addressing the historical underfunding of women’s health issues.

1 reports · 1 sources